TGTX Stock Forecast: TG Therapeutics, Inc. Price Predictions for 2026-2027
The 8 Wall Street analysts covering TG Therapeutics, Inc. hold a median 12-month price target of $75 — +18.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 78 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores TG Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (97): The shares have been drifting up relative to others.
Accruals (13): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
TGTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on TGTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +18.5% from it.
Of the 20 most recent actions, 4 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Nov 2026 | Evercore ISI Group | Maintains | Outperform | $73 → $71 |
| 1 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $78 |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | $65 → $72 |
| 27 July 2026 | B. Riley Securities | Maintains | Buy | $55 → $86 |
| 13 July 2026 | HC Wainwright & Co. | Maintains | Buy | $70 → $77 |
| 7 July 2026 | B of A Securities | Maintains | Underperform | $17 → $20 |
| 6 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $70 |
| 27 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Feb 2026 | JP Morgan | Maintains | Overweight | — |
| 15 Jan 2026 | Goldman Sachs | Maintains | Neutral | — |
| 3 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 6 Oct 2025 | HC Wainwright & Co. | Assumes | Buy | $60 |
| 17 Sept 2025 | B. Riley Securities | Maintains | Buy | — |
| 4 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Nov 2024 | JP Morgan | Maintains | Overweight | — |
| 5 Nov 2024 | Goldman Sachs | Maintains | Neutral | — |
| 5 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Oct 2024 | TD Cowen | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TGTX.
This page is one stock. Monday covers all of them.
TGTX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
TGTX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, TG Therapeutics, Inc. returned +107.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
TGTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 97.4×
- Price / sales
- 11.0×
- Price / book
- 16.0×
- EV / EBITDA
- 48.4×
Cheaper than 8% of US stocks
Cheaper than 11% of US stocks
Cheaper than 4% of US stocks
Cheaper than 7% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- −85.8%
- Gross margin
- 82.9%
- Operating margin
- 21.5%
- Net margin
- —
Higher than 4% of US stocks
Higher than 93% of US stocks
Higher than 81% of US stocks
- Return on equity
- 18.0%
- Return on assets
- 9.2%
- Dividend yield
- —
Higher than 79% of US stocks
Higher than 90% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
TG Therapeutics, Inc. has a market value of $9.8B and an enterprise value of $9.3B.
Revenue in the twelve months to 30 June 2026: $799.5M. The latest quarter grew 70.3% year on year.
Net income over the same four quarters: $441.5M, a 55.2% net margin.
Diluted earnings per share, trailing twelve months: $2.74.
Free cash flow in the twelve months to 30 June 2026: $17.4M.
TG Therapeutics, Inc. spent $178.2M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 97.4×; forward P/E: 25.6× — the forward figure prices analyst consensus estimates, not reported earnings.
TG Therapeutics, Inc. employs 399 people — $2.0M of revenue per employee.
Data provided by Twelve Data
TGTX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at TGTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own TG Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about TGTX
What is the TGTX stock price forecast for 2026-2027?
The 8 Wall Street analysts covering TG Therapeutics, Inc. have a median 12-month price target of $75, with estimates ranging from $21 to $86. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is TGTX stock a buy right now?
Of the 8 analysts covering TG Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks TG Therapeutics, Inc. 78 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank TGTX?
As at 21 Nov 2026, TG Therapeutics, Inc. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).
Will TGTX stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts implies +18.5% from the last close, and Ticker Nerd's factor model ranks TG Therapeutics, Inc. 78 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the TGTX stock forecast for 2030?
No analyst covering TG Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TGTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $86 over the next 12 months.
How has TGTX stock performed over the past year?
TG Therapeutics, Inc. returned +107.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does TG Therapeutics, Inc. do?
TG Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for B-cell mediated diseases. The company’s lead product, BRIUMVI, is an anti-CD20 monoclonal antibody used for adults with relapsing forms of multiple sclerosis, including relapsing-remitting disease, clinically isolated syndrome, and active secondary progressive disease.
About TG Therapeutics, Inc.
TG Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for B-cell mediated diseases. The company’s lead product, BRIUMVI, is an anti-CD20 monoclonal antibody used for adults with relapsing forms of multiple sclerosis, including relapsing-remitting disease, clinically isolated syndrome, and active secondary progressive disease. TG Therapeutics also advances a broader pipeline of therapies, including subcutaneous and intravenous formulations of ublituximab, along with investigational programs such as Azer-cel. Its portfolio is centered on immune-related and hematologic conditions, reflecting a business model built around specialty medicines that target B-cell activity. TG Therapeutics serves patients and healthcare providers in the United States and internationally through its marketed products and development-stage candidates.
CEO Mr. Michael S. Weiss Esq., J.D. · 399 employees · United States · https://www.tgtherapeutics.com